Allon Treads Into the Great Unknown, Alzheimer’s Disease, With New Kind of Drug

4/6/10Follow @xconomy

(Page 2 of 2)

in the cognition score it used, that results were better at a higher dose, and that the results appeared to last—at least through the 12-week study duration.

Allon is hoping that study will entice yet another Big Pharma company to boldly step up with a plan to run the rigorous and expensive trials that will be required by the FDA for a new Alzheimer’s drug. It also has some evidence from a study of 60 patients with schizophrenia which it says suggests there may be a cognitive benefit from taking davunetide. That trial didn’t reach a statistically significant result on the main goal, although it did show such a benefit on a secondary score which measures things like whether a patient can manage their own transportation, banking affairs, and so on, McCauley says.

Last week, Allon released some imaging data which verified that davunetide was having an effect on a biomarker that’s thought to be related to brain health—which might explain why schizophrenia patients appeared to be able to better function on davenutide.

Taken together, this is evidence McCauley says ought to provide a strong signal that Allon is onto something in treating neurodegenerative disease by preventing the buildup of tau tangles. And this is an avenue of research that all the major Big Pharma companies are pursuing in the early stages, along with at least one other biotech company, Singapore-based TauRx.

“We have a bunch of data that suggests this data is working on the tau pathology, and we’d argue ours is the most advanced tau therapy in the world,” McCauley says.

Sounds great, but with a stock price of 56 cents as of yesterday, the world appears to want to see a little more proof. Allon has about $11 million in cash, and access to a $10 million line of credit. The company has about 20 employees, and a cash spending rate of about $750,000 a month, McCauley said last month at the Life Science Innovation Northwest conference in Seattle. That means Allon has enough cash to be able to reach its next set of clinical trial milestones, he says.

One key catalyst would be whether Allon can secure a partner to help tackle monster markets like Alzheimer’s and schizophrenia, which are too big for a small biotech company like Allon to handle on its own. What Allon is banking on for now is a classic rare disease strategy, in which it retains 100 percent ownership of the rights to its drug for a condition called progressive supranuclear palsy, which is a subtype of frontotemporal dementia.

This disease is attractive to Allon for a number of reasons. It’s a severe cognitive disorder that’s thought to affect a small number of people—about 20,000 in the U.S. There are no effective FDA-approved therapies. The diagnosis provides a clear homogenous patient population upfront, so there shouldn’t be any confusion about whether it can enroll patients in a clinical trial with a consistent form of disease. And there are clinically-validated measurements which can say with a high degree of certainty whether the drug is actually helping—rather than a “surrogate” marker which is really an extrapolation that doctors use to try to suggest that a drug might be correlated with the kind of outcome the patient wants.

Given all of those factors, it’s possible that Allon could persuade the FDA to go along with a proposal for a single clinical trial that could pave the way for U.S. market clearance. If Allon can prove that, it’s possible that the company could be ready to file for FDA approval of davunetide for this disorder as soon as 2012. If—and this is still a very big if—Allon can get to that point, it will be in position to tap a market that’s worth an estimated $300 million a year, McCauley says, and it will have solid evidence that will give potential partners confidence to invest in trials for the really big markets of Alzheimer’s and schizophrenia.

“This is the kind of indication that every biotech company dreams of,” McCauley says.

But aren’t pharma partners scared off by the colossal failure of dimebon, from Medivation and Pfizer, in a pivotal clinical trial of Alzheimer’s disease, even after it produced impressive data from a mid-stage trial? McCauley wouldn’t say directly how that flame-out affected his company’s partnership prospects, but he noted that it wasn’t made to work on tau tangles.

“From our perspective, it has opened people’s eyes to different approaches,” McCauley says. “At end of the day, we’ll probably discover it’s really a combination [of tau tangles, and amyloid plaques]. One causes the other, or it involves a feedback mechanism.”

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.